Johann de Bono: h-index, Total Citations, and Citation Map
Johann de Bono's h-index is 166 (848 i10-index, 149,653+ total citations across 1,009+ publications) according to Google Scholar as of August 2026. Johann de Bono is affiliated with Institute of Cancer Research.
Johann de Bono is a researcher affiliated with Institute of Cancer Research, specializing in Cancer. Their work has been cited 149,653 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Johann de Bono's Citation Metrics
Bibliometric impact based on 1,009 indexed publications.
- H-Index
- 166
- i10-Index
- 848
- Total Citations
- 149,653
- Citing Countries
- 80
As of August 2026.
Johann de Bono has an h-index of 166 and 149,653 total citations across 1009 publications, with research cited by institutions in 80 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Johann de Bono's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Increased survival with enzalutamide in prostate cancer after chemotherapy
20125,912
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
The researcher advanced prostate cancer treatment by demonstrating enzalutamide's survival benefits post-chemotherapy and integrating clinical genomics to refine advanced disease management strategies.
The researcher published a seminal NEJM paper demonstrating the efficacy of PARP inhibition in tumors from BRCA mutation carriers, establishing a foundational clinical strategy for targeted cancer therapy.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Johann de Bono's research
Johann de Bono is a researcher in Cancer at Institute of Cancer Research. Their work has been cited 149,653 times across 1,009 publications (h-index 166), according to Google Scholar.
Their most-cited work, “Increased survival with enzalutamide in prostate cancer after chemotherapy” (2012), has accumulated 5,912 citations. Other influential works include “Abiraterone and increased survival in metastatic prostate cancer” (2011) with 5,680 citations and “Abiraterone and increased survival in metastatic prostate cancer” (2011) with 5,641 citations.
Citations of Johann de Bono's research come primarily from China, United States and United Kingdom, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
